Fujirebio joins the Global Health Innovative Technology (GHIT) Fund

Company news

Tokyo, Japan, August 8, 2023 --- H.U. Group Holding Inc., and its wholly owned subsidiary, Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), today announced that Fujirebio has joined the Global Health Innovative Technology (GHIT) Fund.

The GHIT Fund is a Japan-based international public-private partnership fund (PPP) that was formed between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund facilitates collaboration between research organizations in Japan and overseas to accelerate the development of new drugs, in-vitro diagnostics testing solutions, and vaccines for neglected diseases, such as malaria, tuberculosis, and neglected tropical diseases in developing and emerging countries.

“By participating in the fund, Fujirebio will leverage its R&D efforts in the fight against infectious diseases around the world,” stated Goki Ishikawa, President & CEO, Fujirebio Holdings, Inc. “Fujirebio remains strongly committed to a further contribution to addressing global health issues such as improvement of access to healthcare through this participation in the GHIT Fund.”

Fujirebio has joined the GHIT Fund as an Associate Partner.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.